30.5.2007
•
News
M&A
KSB represents Glenmark Pharmaceuticals in acquisition of Medicamenta
Law firm Kocián Šolc Balaštík represented Indian pharmaceutical company Glenmark Pharmaceuticals Ltd. in concluding a deal via its Swiss subsidiary Glenmark Holding SA to acquire a majority shareholding in Medicamenta a.s., a company carrying out business activities in the production, sale and marketing of pharmaceutical products in the Czech Republic and Slovakia.
Glenmark Pharmaceuticals Ltd. is the Indian leader in the development of newmolecules in mainly inflammation and metabolic disorders. The company operatesin more than eighty countries worldwide and the acquisition of Medicamenta a.s.represents a strategic entry into two of the fastest growing markets in the EU.
Other articles
16.10.2025
•
News
KŠB becomes the first major independent law firm on the Czech market to implement the Legora AI platform into its practice, symbolically connecting Czech law with global AI innovation
KŠB continues its tradition of being a pioneer of innovation in the field of legal services. As the first major independent law firm on the Czech market, KŠB has started to utilize Legora, an efficient AI assistant developed specifically for legal professionals, a step which will further strengthen our long-term vision – to combine first class legal expertise with modern technologies, thereby allowing us to deliver top-quality legal services to clients even more efficiently.
13.10.2025
•
News
Contract Competition 2025
KŠB ve spolupráci s největší nezávislou asociací studentů práv na světě ELSA vyhlašuje již 14. ročník soutěže CONTRACT COMPETITION. Soutěž studentům práv nabízí jedinečný pohled do světa transakčního práva pod vedením advokátů přední české advokátní kanceláře.
12.10.2025
•
Financial services
KŠB assisted the J&T Group with the approval of a base prospectus for a CZK 3 billion bond programme
The KŠB team (Martin Krejčí, Vlastimil Pihera, Josef Kříž) provided legal advice to the J&T Group in connection with the approval of the base prospectus for its bond programme. This marks a continuation of KŠB’s long-term advisory role in the group’s financing activities.
